melanoma/slabost navzea

Povezava se shrani v odložišče

Izberite vrsto razvrščanja

Stran 1 iz 492 rezultatov

[Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron].

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Nausea and vomiting develop during surgery, radio- and/or chemotherapy of malignant diseases. Several drugs belonging to different groups of compounds have been used against them in a large scale. After listing these drugs the authors explained their results. Between January 1992 and 1993, 40

A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

BACKGROUND Previous biochemotherapy regimens for metastatic melanoma have required attenuated dosages of interleukin 2 (IL-2) that may have compromised efficacy. METHODS In a phase 2 study, the authors tested sequential temozolomide (75 mg/m2 per day orally for 3 weeks) followed by high-dose, IL-2

Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Reduced glutathione (GSH) production by tumour cells has been proposed as a mechanism for resistance to alkylating agents. High levels of paracetamol can deplete intracellular GSH. We conducted a phase I trial of high dose paracetamol and carmustine (BCNU) in patients with advanced malignant

Phase II trial of N-methylformamide in patients with metastatic melanoma.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Sixteen patients with metastatic melanoma were treated with N-methylformamide (NMF), a polar-planar compound with in vitro cytotoxic and differentiating properties. Sixteen patients were evaluable for toxicity and 14 for response. The initial four patients received an intravenous bolus of NMF 800

Symptomatic malignant melanoma presenting as multiple gastrointestinal polyps.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

We report on a 66-year-old man with a past medical history of gout who presented to his general practitioner (GP) in July 2009 with a history of nausea and intermittent diarrhoea. He had lost 6 kg in weight over 6 months. His GP found he was anaemic and referred him to a gastrointestinal outpatient

Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Methyl-CCNU (NSC-95441) was administered to patients with malignant melanoma in a split dose schedule. Nausea and vomiting were eliminated as clinical problems during therapy. Response rate to the drug seemed somewhat lower than the average of three previously reported disease-oriented phase II

Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

A phase II study was performed to assess the efficacy and toxicity of the combination of cisplatin (CDDP) and tamoxifen (TAM) in patients with metastatic malignant melanoma (MM). A total of 31 consecutive previously untreated patients with unresectable measurable MM were given 100 mg/m2 CDDP every

Fotemustine plus dacarbazine in advanced stage III malignant melanoma.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

19 patients with advanced malignant melanoma were treated with fotemustine and dacarbazine. Data recorded and available for evaluation in all patients included clinical and histopathological parameters of the primary melanoma, blood chemistry, blood cell count, chest X-ray, ultrasound and bone scan

Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

A phase II study of AMSA in previously treated patients with metastatic malignant melanoma was conducted. The dose schedule of AMSA was 40 mg/m2/day for 3 days repeated at 3-week intervals. Among the 30 evaluable patients, one achieved a complete response, one a partial response, and four had minor

Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion and concomitant infusion of either carboplatin or beta-interferon.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Two cases of metastatic malignant melanoma of the lower limb who were treated successfully with hyperthermic isolated limb perfusion are reported. One patient was infused with cisdiammine (1.1-cyclobutanedicarboxylate) platinum (II) (carboplatin, Paraplatin, Bristol-Myers Squibb Company, New Jersey,

Dose escalation of dacarbazine combined with interferon alpha-2a, G-CSF and ondansetron in patients with metastatic melanoma.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

To define the activity of an individually escalated dacarbazine (DTIC) dose combined with interferon-alpha-2a (IFN), granulocyte-colony stimulating-factor (G-CSF) and ondansetron, 20 patients (pts) with metastatic melanoma were treated with DTIC, ondansetron 8 mg iv, G-CSF 300 micrograms sc and IFN

Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Aim: The pharmacokinetics and pharmacodynamics of vemurafenib are characterized by a wide interpatient variability. Since multiple polymorphic enzymes and drug transporters are involved in vemurafenib pharmacokinetics, we studied associations of polymorphisms on vemurafenib-associated

Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE A high-dose interferon alfa (IFN-alpha) regimen as reported in E1684 was unique for the incorporation of an induction phase of maximally tolerated dosages of intravenous (IV) therapy for the initial 4 weeks. This is the only trial that has shown prolongation of overall survival and

Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

In two pilot studies, 55 patients with symptomatic metastases from malignant melanoma were treated with irradiation and concurrent cisplatin. In the first group, cisplatin was given as a continuous intravenous infusion of 20 mg/m2 per day on days 1-5 and 22-26, with irradiation on days 2, 5, 9, 16,

Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE In this Phase 1, multicenter, open-label study, intetumumab (CNTO 95), a fully human anti-αv integrin monoclonal antibody was evaluated for safety, pharmacokinetics, and pharmacodynamic activity in patients with melanoma or angiosarcoma. METHODS Patients with histologically-confirmed

Prejšnji
1
2
3
4
5
6
...
32
33
Naslednji

Pridružite se naši
facebook strani

Herbal & Natural Medicine

Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo

Deluje v 55 jezikih
Zeliščna zdravila, podprta z znanostjo
Prepoznavanje zelišč po sliki
Interaktivni GPS zemljevid - označite zelišča na lokaciji (kmalu)
Preberite znanstvene publikacije, povezane z vašim iskanjem
Iščite zdravilna zelišča po njihovih učinkih
Organizirajte svoje interese in bodite na tekočem z raziskavami novic, kliničnimi preskušanji in patenti

Vnesite simptom ali bolezen in preberite o zeliščih, ki bi lahko pomagala, vnesite zelišče in si oglejte bolezni in simptome, proti katerim se uporablja.
* Vse informacije temeljijo na objavljenih znanstvenih raziskavah